| Aryl carbonyl derivatives as therapeutic agents DR Polisetti, JT Kodra, J Lau, P Bloch, M Guzel, KC Santhosh, AMM Mjalli, ... US Patent 7,384,967, 2008 | 163 | 2008 |
| Aryl and heteroaryl compounds, compositions, and methods of use AMM Mjalli, RC Andrews, MN Arimilli, M Rao, M Guzel, M Bondlela, ... US Patent 7,459,472, 2008 | 125 | 2008 |
| Aryl carbonyl derivatives as therapeutic agents DR Polisetti, JT Kodra, J Lau, P Bloch, M Guzel, KC Santhosh, AMM Mjalli, ... US Patent 7,541,373, 2009 | 119 | 2009 |
| Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model R Piranlioglu, EM Lee, M Ouzounova, RJ Bollag, AH Vinyard, AS Arbab, ... Nature communications 10 (1), 1430, 2019 | 95 | 2019 |
| Aryl carbonyl derivatives as therapeutic agents DR Polisetti, JT Kodra, J Lau, P Bloch, MCV Lopez, N Blume, M Guzel, ... US Patent 7,897,628, 2011 | 90 | 2011 |
| Aryl carbonyl derivatives as therapeutic agents DR Polisetti, JT Kodra, J Lau, P Bloch, MCV Lopez, N Blume, M Guzel, ... US Patent 8,063,081, 2011 | 81 | 2011 |
| Induction of heme oxygenase I (HMOX1) by HPP-4382: a novel modulator of Bach1 activity OC Attucks, KJ Jasmer, M Hannink, J Kassis, Z Zhong, S Gupta, ... PloS one 9 (7), e101044, 2014 | 63 | 2014 |
| On the origins of enantioselectivity in oxazaborolidine mediated carbonyl reductions GB Jones, SB Heaton, BJ Chapman, M Guzel Tetrahedron: Asymmetry 8 (21), 3625-3636, 1997 | 60 | 1997 |
| Refined enantioselective methylation catalysts: improved routes to bifunctional C5 synthons GB Jones, M Guzel, BJ Chapman Tetrahedron: Asymmetry 9 (6), 901-905, 1998 | 49 | 1998 |
| Enantioselective catalysis using planar chiral η6-arene chromium complexes: 1, 2-diols as cycloaddition catalysts GB Jones, M Guzel, SB Heaton Tetrahedron: Asymmetry 11 (21), 4303-4320, 2000 | 33 | 2000 |
| Stereoselective route to mitosanes via tricarbonyl η6 arene chromium complexes GB Jones, M Guzel, JE Mathews Tetrahedron Letters 41 (8), 1123-1126, 2000 | 32 | 2000 |
| Aryl carbonyl derivatives as therapeutic agents DR Polisetti, JT Kodra, J Lau, P Bloch, MC Valcarce-Lopez, N Blume, ... US Patent App. 13/209,565, 2011 | 31 | 2011 |
| Enantioselective cycloadditions catalyzed by face resolved arene chromium carbonyl complexes GB Jones, M Guzel Tetrahedron: Asymmetry 9 (12), 2023-2026, 1998 | 30 | 1998 |
| The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies S Durdagi, T Avsar, MD Orhan, M Serhatli, BK Balcioglu, HU Ozturk, ... Molecular Therapy 30 (2), 963-974, 2022 | 29 | 2022 |
| The pleiotropic effects of TNFα in breast cancer subtypes is regulated by TNFAIP3/A20 KAHHK Eunmi Lee, Maria Ouzounova, Raziye Piranlioglu, Minh Thu Ma, Mustafa ... Oncogene 38 (10.1038/s41388-018-0472-0), 469-482, 2019 | 29 | 2019 |
| Exploiting π shielding interactions in a η6 arene-complexed chiral auxiliary GB Jones, M Guzel Tetrahedron Letters 41 (24), 4695-4699, 2000 | 26 | 2000 |
| Discovery of a small molecule that selectively destabilizes Cryptochrome 1 and enhances life span in p53 knockout mice S Gul, YK Akyel, ZM Gul, S Isin, O Ozcan, T Korkmaz, S Selvi, I Danis, ... Nature Communications 13 (1), 6742, 2022 | 20 | 2022 |
| Synthesis of novel methyl jasmonate derivatives and evaluation of their biological activity in various cancer cell lines BO Sucu, OS Ipek, SO Kurtulus, BE Yazici, N Karakas, M Guzel Bioorganic Chemistry 91, 103146, 2019 | 20 | 2019 |
| Essential parameters and risk factors of the patients for diabetes care and treatment A Bener, FE Keskin, EM Kurtulus, M Guzel, EI Çekirdekçi, P Kadıoğlu, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, S315-S320, 2017 | 19 | 2017 |
| Instant determination of the artemisinin from various Artemisia annua L. extracts by LC‐ESI‐MS/MS and their in‐silico modelling and in vitro antiviral activity … K Dogan, E Erol, M Didem Orhan, Z Degirmenci, T Kan, A Gungor, B Yasa, ... Phytochemical Analysis 33 (2), 303-319, 2022 | 18 | 2022 |
GRAHAM B JONESDIRECTOR OF INNOVATION AT NOVARTIS AGVerified email at novartis.com
